BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in a $4.8 billion all‑cash deal that transfers two approved rare‑disease therapies and late‑stage assets into BioMarin’s portfolio. The boards of both companies approved the transaction; BioMarin will pay $14.50 per Amicus share and expects the deal to close in Q2 2026. The acquisition adds Galafold (Fabry disease) and Pombiliti/Opfolda (Pompe disease) to BioMarin’s commercial lineup as well as U.S. rights to DMX‑200, a phase III candidate for focal segmental glomerulosclerosis. BioMarin said the deal strengthens its rare‑disease commercial footprint and global reach. BioMarin’s management framed the purchase as a scale play to leverage global distribution and extract cost synergies while expanding treatment options for rare enzyme disorders. Share movement and analyst commentary after the announcement reflected investor focus on near‑term revenue accretion and integration risk.